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Abstract
Central nervous system oxygen toxicity (CNS-OT) manifests as tonic-clonic seizures and is a limitation of hyperbaric oxygen therapy (HBOT), as well as of
recreational and technical diving associated with elevated partial pressure of
oxygen. A previous study showed that ketone ester (1,3-butanediol acetoacetate
diester, KE) administration delayed latency to seizures (LS) in 3-month-old
Sprague-Dawley (SD) rats. This study explores the effect of exogenous ketone
supplements in additional dosages and formulations on CNS-OT seizures in
18 months old SD rats, an age group correlating to human middle age. Ketogenic agents were given orally 60 min prior to exposure to hyperbaric oxygen
and included control (water), KE (10 g/kg), KE/2 (KE 5 g/kg + water 5 g/kg),
KE + medium-chain triglycerides (KE 5 g/kg + MCT 5 g/kg), and ketone salt
(Na+/K+bHB, KS) + MCT (KS 5 g/kg + MCT 5 g/kg). Rats were exposed to
100% oxygen at 5 atmospheres absolute (ATA). Upon seizure presentation
(tonic-clonic movements) experiments were immediately terminated and blood
was tested for glucose and D-beta-hydroxybutyrate (D-bHB) levels. While blood
D-bHB levels were significantly elevated post-dive in all treatment groups, LS
was significantly delayed only in KE (P = 0.0003), KE/2 (P = 0.023), and
KE + MCT (P = 0.028) groups. In these groups, the severity of seizures
appeared to be reduced, although these changes were significant only in KEtreated animals (P = 0.015). Acetoacetate (AcAc) levels were also significantly
elevated in KE-treated animals. The LS in 18-month-old rats was delayed by
179% in KE, 219% in KE + MCT, and 55% in KE/2 groups, while only by 29%
in KS + MCT. In conclusion, KE supplementation given alone and in combination with MCT elevated both bHB and AcAc, and delayed CNS-OT seizures.
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Introduction
Hyperbaric oxygen (HBO2) is an FDA-approved medical
therapy for at least 14 conditions including air/gas embolism, decompression sickness, carbon monoxide poisoning, and diabetic wounds, among others. HBO2 involves
breathing pressurized oxygen which results in increased
dissolved oxygen in the blood plasma (Neuman and
Thom 2008). This increased systemic partial pressure of
oxygen (hyperoxia) helps deliver elevated levels of O2 to
various tissues. However, hyperoxia can also generate
excessive oxygen-free radicals which can damage cellular
components through oxidative stress, potentially leading
to significant tissue injury. Consequently, prolonged
HBO2-induced hyperoxia has been shown to increase the
risk, severity, and frequency of seizures (Clark and Thom
1997). This condition, which is a result of elevated tissue
partial pressures of O2, is known as central nervous
system oxygen toxicity (CNS-OT), and occurs when
breathing 100% O2 at barometric pressures (Pb) >2.4
atmospheres absolute (ATA), and poses a limitation on
the use of HBO2 as a therapy (HBOT), and other applications of hyperbaric oxygen, such as recreational and technical divers using elevated O2 partial pressures.
HBO2 has additional applications within the field of
research as a reliable, reproducible, and reversible stimulus for producing generalized tonic-clonic seizures, proving useful for studying the physiological changes that
occur during seizures, as well as for assessing the efficacy
of various anti-seizure methods in animal models. Rodent
studies have shown that the development of hyperoxiainduced seizures can be delayed by food deprivation. In a
previous study, researchers demonstrated that fasting (24–
36 h) could postpone the onset of seizures from HBO2 by
up to 300% (Bitterman et al. 1997). Throughout episodes
of fasting, or with strict adherence to a ketogenic diet
(KD), the body limits glucose availability, which suppresses insulin signaling and mobilizes free fatty acids
(FFA) for fuel from adipose tissue stores (Cahill 2006).
Adipose-derived FFAs are generally impermeable to the
blood brain barrier (BBB), however; hepatic ketogenesis
converts FFA into ketone bodies, b-hydroxybutyrate
(bHB), and acetoacetate (AcAc). Acetone is also produced
in small amounts due to spontaneous decarboxylation of
AcAc. Under normal conditions, the concentration of systemic bHB is very low (≤0.1 mmol/L) and accounts for
<3% of total cerebral metabolism (Hawkins et al. 1971).
Conversely, during extended periods of fasting or strict
KD adherence, ketone bodies accumulate in the blood
(up to ~5–6 mmol/L) and cross the BBB via monocarboxylic acid transporters (MCT1-4), allowing for their
utilization as fuel by the brain (Prins 2007). Under conditions of fasting it has been reported that >60% of brain
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energy metabolism is derived from ketone bodies bHB
and AcAc (Cahill 2006).
Factors that increase oxidative stress may disrupt metabolic control in the brain, and ketone bodies may restore
metabolic homeostasis through a broad array of biochemical, molecular, and cellular changes (Yao et al. 2011;
Simeone et al. 2018). Multiple benefits have been linked
to the metabolic adaptations associated with fastinginduced ketosis, including decreased production of
reactive oxygen species (ROS), improved mitochondrial
function, reduction in inflammation, and expression of
brain-derived neurotrophic factor (BDNF) (Maalouf et al.
2009; Marosi et al. 2016). The clinical efficacy of the KD
has been validated in several animal models of epilepsy.
The KD increases the threshold for seizures induced by
amygdala kindling and GABA antagonists (such as
pentylenetetrazole), and delays the development of seizures in EL mice, SD rats, Frings audiogenic seizure-susceptible, and flurothyl-treated mice (Hori et al. 1997;
Bough and Eagles 1999; Todorova et al. 2000; Mantis
et al. 2004; Bough and Rho 2007; Rho and Sankar 2008).
In rodents with kainic acid-induced seizures, the KD
reduces the risk of developing epilepsy, and the severity
of the symptoms. These effects may be explained by the
reduction in hippocampal excitability and decreased
supragranular mossy fiber sprouting (Muller-Schwarze
et al. 1999; Noh et al. 2003; Xu et al. 2006). The
improvement observed with ketone utilization is similar
to that observed with therapeutic doses of anti-epileptic
drugs (AEDs) (Bitterman and Katz 1987; Tzuk-Shina
et al. 1991) and novel anticonvulsants that inhibit excitatory glutamatergic neurotransmission (Chavko et al.
1998).
Based upon these results and other studies, nutritional
ketosis has been shown to be an effective treatment
option for patients with drug-resistant seizure disorders
(Freeman and Kossoff 2010). The clinical use of therapeutic ketosis is well documented in both children and adults
(Klein et al. 2010). Despite multiple studies demonstrating the efficacy of fasting and ketosis in seizure reduction,
the molecular mechanisms have remained largely
unknown. However, a recent study using absence seizureprone Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats has
proposed the involvement of the adenosinergic A1 receptor (AA1R) pathway (Kovacs et al. 2017). An additional
study suggests other stabilizing mediators could be
involved, including polyunsaturated fatty acids, which
modulate ion channels (Rogawski et al. 2016).
The anticonvulsant effects of the KD typically correlate
with increased concentrations of ketone bodies in the
blood, particularly AcAc and acetone (Bough and Rho
2007; Mcnally and Hartman 2012). However, when compared to prolonged fasting, the levels of blood ketones
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associated with the KD are often limited due to the difficulty of nearly complete carbohydrate restriction required
(Cahill 2006). Ketone supplementation with esters of
bHB or AcAc can induce a rapid and sustained therapeutic ketosis that mimics the effects of prolonged fasting or
a rigid KD without dietary restriction (Desrochers et al.
1995; Brunengraber et al. 1997). Moreover, previous
research has established that orally administered esters of
bHB are tolerated and safe in rats (Clarke et al. 2012), as
well as humans (Clarke et al. 2012). In 2013, D0 Agostino
et al. investigated whether a ketone diester [R,S-1,3-butanediol acetoacetate diester (BD-AcAc2, KE)] (Ciraolo
et al. 1995; Desrochers et al. 1995; Puchowicz et al.
2000), could replicate fasting and the KD’s ability to
increase latency to seizure (LS). Using 3 months old SD
rats, they showed that KE is effective in causing a rapid
(<30 min) and sustained (> 4 h) elevation of AcAc
(>3 mmol/L) and bHB (>3 mmol/L), and delayed LS by
574  116% compared with control (water) due to the
effect of AcAc and acetone, but not bHB alone
(D’Agostino et al. 2013). During that study 5 ATA O2
pressure was tested. Therefore, to make our results comparable we used the same conditions for the present
study. In a more recent study, the ability of KE to elevate
blood bHB rapidly (<30 min) and for a sustained period
(8 h) was further demonstrated in SD rats (Kesl et al.
2016).
Medium-chain triglyceride (MCT) oil contains fatty
acids 8–10 carbons in length. Upon ingestion, these medium-chain fatty acids are readily converted to bHB causing a rapid elevation in blood ketones. It has been
demonstrated that co-ingestion of MCTs along with other
ketogenic supplements prolonged ketone elevation (Kesl
et al. 2016). Additionally, MCTs have been previously
shown to have antiseizure effects (Augustin et al. 2018),
therefore in this study we also tested ketogenic agents
combined with MCTs.
The potential for ketone supplementation to circumvent the dietary restriction associated with the KD to
achieve therapeutic ketosis has been previously discussed
(Ari et al. 2015; D’Agostino 2016). This strategy to induce
nutritional ketosis would be favored by those unwilling or
unable to follow a strict KD. From an operational perspective, the use of ketone supplementation offers practical advantages due to the rapid onset and ability to titrate
the dosage and formulation for individual response, pharmacokinetic profile and associated mechanistic properties
(Bough and Eagles 1999; Kovacs et al. 2017).
The specific aim of this study was to expand upon previous research establishing the link between therapeutic ketosis
and the resulting antiseizure effects. We hypothesized that
ketogenic strategies that elevate both bHB and AcAc would
have the greatest potential delaying CNS-OT. Thus, we

Delaying CNS-OT Seizures with Exogenous Ketones

explored the effect of different dosages and combinations of
exogenous ketone supplements on CNS-OT seizures in an
older age group of male SD rats (18 months), which is used
to model middle age in humans.

Materials and Methods
Animal procedures and treatment groups
All animal procedures were done in accordance with the
University of South Florida Institutional Animal Care and
Use Committee (IACUC) guidelines. All protocols were
previously approved by the University of South Florida
Institutional Animal Care and Use Committee (PHS
Assurance No. A4100- 01; and fully accredited by AAALAC as Program No. 000434) and by the Director for
Veterinary Affairs, Department of the Navy, Bureau of
Medicine and Surgery.
Eighteen-month-old male SD rats (470–720 g, n = 42,
Harlan) were given normal rodent chow (Envigo; 19%
protein; 75% carbohydrate; 6% fat) and water ad libitum
and kept on a 12-h light/dark cycle. The rats were
assigned to one of five treatment groups: control (water,
n = 9), 1,3- butanediol acetoacetate diester (BD-AcAc2,
KE, 10 g/kg, n = 9), KE/2 (KE, 5 g/kg + 5 g/kg water,
n = 8) and KE + MCT (KE 5 g/kg + MCT 5 g/kg,
n = 9). The ketone salt (KS) is formulated as a sodium/
potassium- bHB salt (Na+/K+bHB) that is a 50%
solution containing approximately 375 mg/g of pure D/LbHB and 125 mg/g of Na+/K+. The Na+ and K+ are balanced to be in a 1:1 ratio. KS was mixed with equal parts
MCT (KS 5 g/kg + MCT 5 g/kg, n = 7). The rats received
one dose of their respective ketogenic agent by intragastric oral gavage 60 min prior to being exposed to hyperbaric conditions.

Acquisition/analysis software
Raw video recordings were collected using DSI Ponemah
software (version 4.90, P3 Ponemah Physiology Platform). GraphPad PRISM (version 3.03) was used for all
statistical analyses. All values in this work were reported
as means  SEM of measurement. Analysis of data was
performed using One-way ANOVA and two-tailed,
unpaired t-tests. Values were considered significant when
P < 0.05. Prior to experiments it was determined that
outliers (2SD) would be excluded if represented as mean
data.

Hyperbaric chamber
The hyperbaric system was composed of two main parts:
Plexiglass chamber with a three-liter capacity (Diamond
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Box, Buxco, Electronics Inc., model PLY3114) where the
rat was kept during the experiment (kept at 100% O2),
and a hyperbaric chamber pressurized with air (Reimers
Systems, 7.8 ATA MWP) that held the Plexiglass chamber and operated as the pressure vessel. Pressuring only
the Plexiglass chamber with 100% O2 averts the potential
fire hazard of needing to pressurize the larger chamber
with 100% O2. An air compressor (oil-less rotary scroll
compressor – model DK6086, Powerex) was connected to
both chambers.

HBO2 exposures (dive profile) and seizure
detection
Thirty minutes after treatment, rats were placed in the
hyperbaric chamber, where they were given 10 min to
acclimate to the chamber, after which it was filled with pure
oxygen, and the rats were allowed another 15 min to acclimate to the new atmosphere. The outer chamber was pressurized using air (capacity ~205 L). Next, both chambers
were compressed to 5 atmospheres absolute (ATA) in parallel at a rate of approximately 1 ATA/min. The rat was
visually monitored continuously via a live camera. Rats
remained at 5 ATA until physical symptoms of CNS-OT
seizures were exhibited, as defined in the following section.
LS was calculated from the moment at which the internal
and the external chambers reached 5 ATA until the onset of
convulsions (criteria listed below). After the onset of seizure, which was determined by a blinded experimenter, the
Plexiglass chamber was flushed with air to quickly terminate the seizure, and both chambers decompressed to sea
level at a rate of 1 ATA/min until gas within the chamber
normalized to atmospheric pressure and composition.
Experiments were immediately terminated by the
blinded experimenter if rats exhibited signs of pulmonary
oxygen toxicity (observed as gasping and/or difficulty
breathing) or exposure time at 5 ATA reached 120 mins.
If either of those criteria were fulfilled, the inner chamber
was flushed with air to reverse the effects of HBO2, and
the chamber was decompressed at a rate of 1 ATA/min.

Seizure definition and severity scores
Tonic-clonic seizures were defined when rats exhibited
two or more of the following symptoms: head bobbing
up and down, blinking, elevation of one or two front
paws, most often with opened toes or pushing the
ground, that lasted for at least 10 s, or multiple and
intense shakes or thrashing. A scoring system (ranging
from 0 to 3) was used to record seizure severity
(Table 1). A score of 0 indicated that no tonic-clonic seizure was observed during the experiment. A score of 1
indicated that the animal showed mild symptoms, with
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seizures not lasting more than 10 sec and no signs of
exhaustion shown post-seizure. A score of 2 indicated
that the animal displayed symptoms of an intense seizure
for less than 10 sec, or subtle symptoms for longer than
10 sec. A score of 3 indicated that symptoms of a violent
seizure were displayed, with intense, jerky movements for
more than 10 sec, along with signs of exhaustion for an
extended period post-seizure.

Synthesis and formulation of ketogenic
compounds
KE was synthesized as previously described by D’Agostino
et al. (2013). KS is a novel agent that was mixed into a
50% solution supplying approximately 375 mg/g of pure
bHB and 125 mg/g of Na+/K+ in a 1:1 ratio. Both KE
and KS were developed and synthesized in collaboration
with Savind (Seymour, IL). Human food grade MCT oil
(~60% caprylic triglyceride/40% capric triglyceride) was
purchased from Now Foods (Bloomingdale, IL). KS or
KE were mixed with MCT in a 1:1 (by weight) ratio, generating the KS+MCT and KE+MCT combinations.

Measurement and analysis of blood glucose
and ketones
Blood was withdrawn from the rats via the saphenous
vein. Blood concentrations of glucose and D-bHB were
determined utilizing a commercially available glucose and
ketone monitoring system (Abbott Labs: Precision Xtra)
immediately following removal from the hyperbaric
chamber. Total blood bHB was estimated to be higher for
KE and KS since this meter does not detect L-bHB. In
order to document the level of AcAc that was present in
the animals when they were exposed to the hyperbaric
oxygen 1 month later some of the animals (those remaining alive) received another treatment by oral gavage, and
60 min later whole blood samples (300 lL) were collected
into Eppendorf tubes in order to document AcAc levels
that correlate to hyperbaric exposure time. Due to the
limited number of aged animals, only control (water,
n = 3), KE (n = 5), KE+MCT (n = 5) and KE/2 (n = 5)
treatments were tested for AcAc and the animals were not
matched with the treatment received during the previous
experiment, so AcAc levels and LS was not correlated.
Samples were processed for the detection and quantification of AcAc at Case Western Reserve University, Mouse
Metabolic Phenotyping Center. Whole blood was collected, stabilized with cold 0.2 mol/L NaB2H4 to convert
AcAc into [2-2H] bHB, and then immediately frozen on
dry ice. Samples were stored at 80°C until analyses.
Briefly, internal standard of [2,4-13C2] bHB was added to
the treated blood samples (15 lL) and bHB was extracted
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Table 1. Definition of seizure severity categories used during the study.
Severity score
0
1
2
3

Symptoms
No tonic-clonic seizure was observed during the experiment
Mild and short (<10 sec) seizures. No postictal symptoms
Intense tonic-clonic seizure for less than 10 sec or subtle symptoms for longer than 10 sec
Violent tonic-clonic seizure for more than 10 sec. Postictal signs of exhaustion for an extended period

and converted to its trimethylsilyl (TMS) derivative by
reacting lyophilized sample with 80 lL of bis(trimethylsilyl)
trifluoroacetamide + 10%
trimethylchlorosilane
(Regis, Morton Grove, IL) for 30 min at 75°C. di-TMS
derivative of bHB was analyzed by gas chromatographymass spectrometry (GC–MS) using an Agilent 5973 mass
spectrometer, linked to a 6890 gas chromatograph
equipped with an autosampler. Briefly, bHB (M/Z 233)
was detected under the condition of electron ionization
(EI) mode. M1 ion (M/Z 234) corresponding to [2-2H]
bHB represented AcAc amount present in the sample
after appropriate background subtraction. M2 ion (M/Z
235) corresponded to an internal standard and was used
to calculate AcAc and bHB sample concentrations.

Results
Latency to seizure and seizure severity
Significantly delayed LS (in sec) from CNS-OT was documented in KE+MCT group (P = 0.049; Fig. 1A), when all
animals included in the experiment were considered. When
outliers were removed (based on 2 standard deviation;
Fig. 1B) LS was significantly delayed in the KE
(P = 0.0003), KE/2 (P = 0.023), and KE+MCT (P = 0.028)
groups. The KS+MCT treatment group showed a trend for
delayed CNS-OT, but was not significant when compared
to control (water). It was determined that LS was also significantly different between KE and KE/2 groups
(P = 0.011). In terms of percentage, the KE group experienced a delay to seizure of 179%, as compared to the control group, while the KE+MCT group showed a trend of
greater anti-seizure effect with LS = 219%, however, these
groups were not statistically different (Fig. 1C). The KE/2
group delayed seizure by 55%, while the KS+MCT group
showed a trend, but did not significantly influence LS.
Moreover, the severity of seizures, determined by the
blinded experimenter (Fig. 1D), was significantly less in KE
(P = 0.015) and showed a trend towards less severity without significance in KE/2, and KE+MCT groups, when compared to control (Fig. 2). The LS in young and aged rats
was not significantly different (P = 0.07).

Blood bHB, AcAc, glucose, and body weight
All treatment groups experienced a significantly higher
blood D-bHB, compared to control (Fig. 3A). Treatment
with KE (P < 0.0001) and KE+MCT (P = 0.0002)
resulted in higher bHB levels approximately five- to sixfold when compared to control. The KE/2 group
(P = 0.0012) had higher bHB level then the control by a
factor of approximately three, while it was about two
times higher in the KS+MCT (P = 0.0006) group. There
was a strong positive correlation between bHB levels and
LS when all treatment groups were considered
(R2 = 0.588; Fig. 3B) and in the KE group alone
(R2 = 0.71). The elevation of bHB in KE-containing treatment groups was also associated with an elevation of
AcAc. AcAc was significantly higher in all treatment
groups compared to control (P < 0.0001; Fig. 3C). In
groups treated with KE, KE+MCT and KE/2 the AcAc
levels were higher than control (water) by factors of 16,
15, and 14, respectively. Blood glucose and body weight
were not significantly different between the treatment
groups and control (Fig. 4).

Discussion
In this study we examined the effect of different dosages
and combinations of exogenous ketone supplements in
the time-course of CNS-OT seizures, which remains a limitation of HBOT, as well as recreational and technical
divers using enriched O2 mixes, including closed-circuit
rebreather diving technologies employed by the United
States Navy Sea, Air, and Land (SEAL) operations. The LS
was significantly delayed in the KE, KE/2 and KE+MCT
groups and this correlated with significant elevations in
both bHB and AcAc levels compared with control (water).
The LS was not significantly delayed in the KS+MCT
group (bHB precursors), which was associated with lower
bHB levels and no elevation of AcAc. In addition, the
severity of seizures was significantly less in the KE group
and a trend towards lower severity could be observed in
all other ketone supplement groups. In 3-month-old juvenile rats the KE delayed seizure by 574% compared with
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Figure 1. Delayed latency to seizure in response to ketone supplementation in Sprague-Dawley rats. (A) A scatter plot (including outliers)
demonstrating the latency to seizure (LS) for all specimens in the different treatment groups. KE + MCT group had significantly increased LS
compared to control (P = 0.049). (B) The latency to seizure (LS) is presented after the exclusion of the outliers (2SD) from each treatment group.
The LS was significantly delayed in the KE (P = 0.0003), KE+ MCT (P = 0.028) and KE/2 (P = 0.023) treatment groups when compared to control.
LS in KE group was significantly higher than in KE/2 group (P = 0.011). (C) The percent change in latency to seizure (LS) when compared to control.
(D) The blinded experimenter opening the hyperbaric chamber after determining seizure severity and performing gradual decompression.

Figure 2. A bar graph displaying the severity of the seizure for all
groups. The severity of seizures was significantly less in the KE
group (P = 0.015), when compared to control.

control (D’Agostino et al. 2013), while the LS in 18month-old rats was delayed by 179% in the KE group,
219% in the KE + MCT group, and 55% in the KE/2
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group. From these results, we demonstrated that rats in
older age group, correlating to human middle age, showed
delayed latency to CNS-OT seizures. The LS was less pronounced than in younger rats, although still comparable to
high-dose, anti-seizure drugs. Thus, we speculate that combining ketogenic supplements with AEDs, may produce
more favorable effects on LS while mitigating adverse drug
effects. The difference in LS observed in the two age groups
may be due to age-dependent alterations in O2 tolerance,
changes in brain ketone metabolism, or changes in the neuropharmacological targets with aging. As the control
groups in the two studies did not differ significantly in LS,
this may provide support for the hypothesis that ketone
metabolism and associated signaling change with age. One
shortcoming of the study is that we have not yet characterized some of these ketone supplement formulations in
younger rats. Further studies are needed to assess agerelated changes in ketone-induced neuroprotection and to
determine how chronic administration influences the neuroprotective antiseizure effects, as was done in other model
systems (Kovacs et al. 2017).
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Figure 3. Changes in blood ketone levels in response to ketone supplementation. (A) All treatment groups showed a significant increase in
blood D-bHB concentrations. Compared to the control, the KE (P < 0.0001) and KE+MCT (P = 0.0002) groups had a higher level of D-bHB by a
factor of five, KE/2 group (P = 0.0012) by a factor of three, and the KS+MCT group (P = 0.0006) by a factor of approximately two. (B) There
was a positive correlation between latency to seizure (LS) and blood D-bHB concentration (R2=0.5889). (C) The AcAc levels measured 60 min
after treatment for the different treatment groups. The KE (P < 0.0001), KE+MCT (P < 0.0001) and KE/2 (P < 0.0001) groups had significantly
elevated AcAc levels, compared to control.

Figure 4. There was no significant difference in blood glucose levels (A) measured after removal from the chamber and in body weights (B)
between the treatment groups and control.

While all contributing mechanisms of KE-induced neuroprotection against CNS-OT still need to be elucidated,
the findings from this study and other reports suggest a
multifactorial contribution to the anti-epileptic effect of
ketone bodies (Simeone et al. 2018). The current study
reinforces previous conclusions that seizure resistance is
correlated with elevated ketone levels in the blood (Bough
and Rho 2007; Mcnally and Hartman 2012). LS was significantly increased in KE compared to KE/2 group, suggesting a dose–response effect. Moreover, the trend of
delayed seizure in KE+MCT group (219%), when compared to the KE group (179%), suggest that the addition
of MCTs may provide an additive affect, however, more
work would be necessary to confirm this. Further experiments are needed to examine the mechanisms associated
with antioxidant neuroprotection (Maalouf et al. 2007;
Kim et al. 2010; Milder et al. 2010) and enhanced metabolic efficiency (Veech 2004) that may also be contributing to these neuroprotective effects against the acute
oxidative stress stimulus of HBO2.

The neuroprotective effect of fasting and the KD –
specifically against seizures – has been well-studied in animal models and humans, and was found to be positively
correlated with levels of ketones (Bough and Rho 2007;
Mcnally and Hartman 2012). However, both ketogenesis,
and the seizure protection it confers, are reversed via consumption of carbohydrates or surplus protein. Therefore,
exogenous ketone supplementation, such as those tested
here, may be a more practical mitigation strategy for
CNS-OT, as well as a valuable option for epileptic
patients who have issues adhering to the KD (Rho et al.
2002). Our findings suggest that the antiseizure effect of
therapeutic ketosis induced with supplementation is
observed even in older rats eating a standard carbohydrate-based diet.

Effects of the ketone intervention groups
It has been proposed that bHB alone, the primary ketone
in circulation, does not impact CNS-OT in a significant

ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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manner if elevated independently from AcAc. However,
bHB elevated with both AcAc and acetone has been
shown to delay seizures in CNS-OT (D’Agostino et al.
2013) and in other animal models of seizures (Likhodii
et al. 2008; Rho and Sankar 2008). All treatment groups
that experienced a delay of CNS-OT received KE, which
is a precursor to bHB, AcAc and acetone. There was a
strong positive correlation between blood bHB levels and
LS in the KE group (R2 = 0.711) and when all KE-associated treatment groups were considered (R2 = 0.588),
presumably due to KE-induced increases in AcAc and
acetone (D’Agostino et al. 2013). While D-bHB was elevated within the serum of treated animals, it is important
to note that the KE and KS used in this study are composed of racemic mixtures resulting in elevations of both
D-bHB and L-bHB. Thus, the reported value of measured
bHB only reflects that of D-bHB, not of total bHB. Similarly, KE, KE/2, and KE+MCT groups had significantly
higher AcAc levels compared to the control. Acetone was
previously reported to play a potential antiseizure role
against CNS-OT with KE administration. It can be estimated that approximately 20% of AcAc spontaneously
decarboxylates to acetone (D’Agostino et al. 2013), but
since there is enzymatic interconversion between bHB
and AcAc it becomes difficult to attribute the anti-seizures effects to AcAc or acetone alone. Indeed, acetone
alone is comparable or better than some broad-spectrum
anticonvulsants (Likhodii et al. 2008), suggesting it may
have contributed independently to the observed antiseizure effects.

Ketone-induced neuroprotection
There is increasing experimental evidence that ketoneinduced anti-seizure properties function through a
multiplicity of mechanisms associated with suppression of
neuronal hyperexcitability, inflammation, and redox stress.
These mechanisms include but are not limited to: (Ari et al.
2015) activation of inhibitory adenosine and ATP-sensitive
potassium channels; (Augustin et al. 2018) enhancement of
mitochondrial function and reduction in oxidative stress;
(Bitterman and Katz 1987) attenuation of neuronal
excitability by modulating vesicular glutamate transporters
or VGLUTs (notably, AcAc), and (Bitterman et al. 1997)
enhancement of central c-aminobutyric acid (GABA) synthesis. Other novel actions more recently reported include
inhibition of NLRP3 inflammasome assembly and decreasing the activity of histone deacetylases (HDACs). This
study supports the in vivo antiseizure effects of bHB, AcAc,
and ACE, as reported previously (Simeone et al. 2018).
However, the question of whether one specific ketone or a
combination of these ketone bodies affords even greater
efficacy has not yet been answered.
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Ketone ester-induced metabolic therapy
Another proposed mechanism by which ketones delay
CNS-OT involves enhancing mitochondrial efficiency
(Veech 2004). It has been well established that ketones
can replace glucose as the primary fuel (>50%) for brain
energy metabolism during periods of limited glucose
availability resulting from starvation or carbohydrate
restriction (Cahill 2006). Previous studies in rats show
that starvation delays the onset of CNS-OT (Bitterman
et al. 1997), presumably via a fundamental shift in brain
energy metabolism away from glucose utilization. Starvation (24–36 h) also delays the latency to seizure from
HBO2 by up to 300%, which is equally – or more effective than – high doses of clinically approved anti-epileptic
drugs (AEDs) (Bitterman and Katz 1987; Tzuk-Shina
et al. 1991) or experimental anticonvulsants that block
excitatory glutamatergic neurotransmission (Chavko et al.
1998). Based upon the hypothesis that CNS-OT is the
result of metabolic dysfunction, secondary to hyper-excitability and oxidative stress from hyperoxia, therapeutic
ketosis should be considered as a metabolic-based therapy. This study identifies several exogenous ketone supplement formulas that show therapeutic efficacy against
CNS-OT and would be likely candidates for translational
studies in human subjects.

Conclusions
Previous experiments have established the relationship
between bHB, AcAc, and seizure resistance in younger
rats. This study extends those findings and demonstrates
the utility of additional combinations of ketone supplementation as a practical strategy for mitigating CNS-OT
in a rodent age group that rather models middle-age
humans. These results indicate that potentially new combinations of ketone supplements, specifically KE-based
formulas, that elevate both bHB and AcAc, can be used
to effectively delay seizures. Further advantage of these
ketone supplement formulas may be better palatability,
safety, and effectiveness; therefore, we urge further investigation of these compounds as potential therapeutics for
resilience against CNS-OT.
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